Phase III Study to Evaluate the Efficacy and Safety of AD-209

Launched by ADDPHARMA INC. · Apr 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called AD-209 to see how effective and safe it is for treating high blood pressure, also known as essential hypertension. The trial is currently looking for participants, and anyone aged 39 and older can join. To be eligible, you need to sign a consent form agreeing to participate and meet some other specific requirements. However, if you experience a drop in blood pressure when standing up, known as orthostatic hypotension, you won't be able to take part in this study.

If you decide to participate, you’ll undergo regular check-ups to monitor your health and see how well AD-209 works for you. This is an important opportunity to help researchers understand more about this potential treatment for high blood pressure. If you have any questions or concerns about the trial, don’t hesitate to ask your healthcare provider for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Signed informed consent
• • Other inclusions applied
• Exclusion Criteria:
• • Orthostatic hypotension with symptom
• • Other exclusions applied